Progyny, Inc. (NASDAQ:PGNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Progyny, Inc. (NASDAQ:PGNY) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.9091.

Several equities analysts have issued reports on PGNY shares. Truist Financial decreased their price objective on shares of Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research report on Wednesday, January 21st. BTIG Research dropped their price target on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Finally, Wall Street Zen downgraded Progyny from a “buy” rating to a “hold” rating in a report on Saturday.

Progyny Price Performance

PGNY stock opened at $16.60 on Monday. The business has a 50 day moving average price of $19.77 and a 200 day moving average price of $22.17. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 25.54, a PEG ratio of 0.96 and a beta of 0.99. Progyny has a fifty-two week low of $16.28 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The company had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, sell-side analysts anticipate that Progyny will post 0.6 EPS for the current year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 7,455 shares of company stock worth $129,515. 9.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Several hedge funds have recently made changes to their positions in PGNY. California State Teachers Retirement System lifted its position in Progyny by 0.7% during the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after acquiring an additional 457 shares during the period. Teza Capital Management LLC increased its holdings in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares during the period. Leibman Financial Services Inc. raised its stake in shares of Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock worth $1,192,000 after purchasing an additional 528 shares during the last quarter. Aristides Capital LLC lifted its holdings in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after purchasing an additional 528 shares during the period. Finally, Oxford Asset Management LLP grew its position in Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.